Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Sodium tetradecyl sulfate
STD Pharmaceutical Products Ltd
C05BB; C05BB04
Sodium tetradecyl sulfate
0.2 percent weight/volume
Solution for injection
Product subject to prescription which may not be renewed (A)
Sclerosing agents for local injection; sodium tetradecyl sulfate
Marketed
2001-05-04
PACKAGE LEAFLET: INFORMATION FOR THE USER FIBRO-VEIN 0.2% W/V, 0.5% W/V, 1% W/V AND 3% W/V SOLUTION FOR INJECTION Sodium tetradecyl sulphate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS INJECTION. Keep this leaflet. You may need to read it again while you are receiving your treatment. If you have any further questions, please ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Fibro-Vein Injection is and what it is used for 2. Before you are given Fibro-Vein Injection 3. Your treatment with Fibro-Vein Injection 4. Possible side effects 5. How to store Fibro-Vein Injection 6. Further information 1. WHAT FIBRO-VEIN INJECTION IS AND WHAT IT IS USED FOR The name of your medicine is Fibro-Vein Injection, which contains the active ingredient sodium tetradecyl sulphate. This injection belongs to a group of medicines called sclerosants. Sclerosants are chemical agents, when injected into the affected vein causes the lining of the vein walls to swell and the walls stick together. This stops the flow of blood and the vein turns into scar tissue. In a few weeks, the vein should fade. Different strengths of Fibro-Vein Injection are used in the treatment of varicose veins, minor venules and spider veins. 2. BEFORE YOU TAKE FIBRO-VEIN INJECTION YOU SHOULD NOT TAKE FIBRO-VEIN INJECTION IF YOU: are allergic (hypersensitive) to sodium tetradecyl sulphate or to any of the other ingredients in Fibro-Vein Injection (see section 6, Further information) cannot walk due to any reason have severe inflammation of veins in the legs(acute phlebitis) have blood clots in your veins (thrombosis) have twisted veins (varicose veins) caused by pelvic or abdominal tumours are significantly overweight have any ki Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fibro-Vein 0.2% w/v Solution for Injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Contains sodium tetradecyl sulfate 0.2% w/v (equivalent to 2 mg/ml). Excipients: Contains benzyl alcohol 20 mg/ml, sodium 2.43 mg/ml and potassium 0.29 mg/ml. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear, colourless solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the treatment of minor venules and spider veins (venous flares) by injection sclerotherapy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ROUTE OF ADMINISTRATION The smallest needles should be used to perform the injection which should be made slowly so that the blood content of these veins is expelled. In the treatment of spider veins an air block technique may be used. RECOMMENDED DOSES AND DOSAGE SCHEDULES _Adults_ 0.25 to 1.0ml of 0.2% fibro-vein injected intravenously at a maximum of 10 sites (maximum 10ml). _Children_ Not recommended in children. _Elderly_ As for adults. 4.3 CONTRAINDICATIONS 1. Allergy to sodium tetradecyl sulfate or to any component of the preparation. 2. Patients unable to walk due to any cause. 3. Patients currently taking oral contraceptives. 4. Significant obesity. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _0_ _3_ _/_ _1_ _2_ _/_ _2_ _0_ _1_ _5_ _C_ _R_ _N_ _ _ _2_ _1_ _6_ _5_ _9_ _8_ _0_ _p_ _a_ _g_ _e_ _ _ _n_ _u_ _m_ _b_ _e_ _r_ _:_ _ _ _1_ 5. Acute superficial thromb Read the complete document